SEWA S. LEGHA, M.D., F.A.C.P.; HUGH L. DAVIS, M.D.; FRANCO M. MUGGIA, M.D., F.A.C.P.
The most useful new hormonal therapy against estrogen receptor-containing metastatic breast cancer is the development of antiestrogenic agents such as nafoxidine and tamoxifen. Both of these drugs possess antitumor activity comparable to that of other additive hormonal agents, and they are better tolerated for lack of any serious toxicity. The clinical usefulness of antiprolactin drugs in breast cancer is at present limited. Adrenal suppression using aminoglutethimide has been shown to induce useful remissions. We discuss the implications of new treatment modalities for the future management of disseminated breast cancer.
LEGHA SS, DAVIS HL, MUGGIA FM. Hormonal Therapy of Breast Cancer: New Approaches and Concepts. Ann Intern Med. ;88:69–77. doi: 10.7326/0003-4819-88-1-69
Download citation file:
Published: Ann Intern Med. 1978;88(1):69-77.
Breast Cancer, Hematology/Oncology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use